Problem

Granza Bio is addressing two linked problems in oncology and genetic medicine: many treatments are either ineffective or toxic, and promising therapeutic payloads are difficult to deliver to the right tissue. The company’s launch materials claim that roughly half of cancer patients receive treatments that are ineffective and produce avoidable side effects, while Oxford describes current cancer therapies as reducing patients’ quality of life and survival because of toxicity. The economic opportunity is therefore to improve the therapeutic index of potent medicines—making them more selective, effective, and potentially easier to develop—although Granza has not published a quantified cost-saving estimate.

The clearest initial use case is targeted cancer treatment, particularly for hard-to-reach solid tumors such as glioblastoma. Granza says its attack particles have demonstrated cancer-killing activity in brain, ovarian, lung, and skin cancers, with the ability to cross the blood-brain barrier while sparing healthy tissue. The same approach could eventually extend to autoimmune disease and infections.

Product / Service

Granza is developing a biomimetic therapeutic-delivery platform built around engineered “precision shells.” These shells are intended to package and direct different payloads—including RNAs, proteins, genetic modifiers, and immune-system attack particles—to selected tissues while minimizing immune activation. The company’s foundational technology is based on supramolecular attack particles: autonomous killing entities released by cytotoxic immune cells that carry proteins such as granzymes and perforins. Granza’s broader positioning is programmable therapeutics that can re-arm exhausted immune cells with newly programmed ammunition.

The delivery platform is designed to address tissue tropism, immunogenicity, stability, and access to difficult organs, while combining the potency of cellular immune therapies with a more standardized, potentially off-the-shelf delivery format. Granza appears to be pursuing a platform-and-partnership model rather than selling a currently marketed drug: its public materials invite partnership and licensing discussions, and external company descriptions characterize the offering as collaborative delivery development involving payload formulation and targeting strategy.

Market

Granza competes at the intersection of therapeutic delivery, drug discovery, genetic medicine, immuno-oncology, and broader biotechnology. Its platform-level ambition is broader than a single cancer drug: the same delivery infrastructure is intended to support multiple payload classes and disease areas. PitchBook categorizes the company primarily under drug discovery and places it in the life-sciences and oncology verticals. It lists Aronora, Meditope Biosciences, Inovio Pharmaceuticals, and Mestag Therapeutics among a broader set of 59 database-defined competitors, although these should be viewed as adjacent or broad comparables rather than proof of direct head-to-head competition.

Public traction is consistent with an early, privately held seed-stage biotech rather than a commercial company. Granza raised an oversubscribed $7.14 million seed round in 2024 led by Felicis and Refactor with participation from Y Combinator and other investors. By 2025–2026, it was publicizing a preprint describing scalable isolation and potent cytotoxic activity for its attack particles, and it won Best Pitch and Best Scientific Explanation at the 2026 BioEscalator Pitch Battle. No revenue, paying customers, or human clinical program is disclosed in the reviewed materials, so Granza appears pre-revenue and preclinical, with value presently concentrated in its research platform, intellectual property, and future partnering potential.